SEC Comment Letter 0000000000-24-009341 to MiNK Therapeutics, Inc. (INKT) (CIK 0001840229) (INKT)
MiNK Therapeutics, Inc. (INKT) (CIK 0001840229)
Date: Aug. 15, 2024 · CIK: 0001840229 · Accession: 0000000000-24-009341
AI Filing Summary & Sentiment
File numbers found in text: 333-281522
Letter
August 15, 2024 Jennifer S. Buell, Ph.D. Chief Executive Officer MiNK Therapeutics, Inc. 149 Fifth Street, Suite 500 New York, NY 10010 Re:MiNK Therapeutics, Inc. Registration Statement on Form S-3 Filed August 13, 2024 File No. 333-281522 Dear Jennifer S. Buell, Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Zachary R. Blume
Show Raw Text
August 15, 2024
Jennifer S. Buell, Ph.D.
Chief Executive Officer
MiNK Therapeutics, Inc.
149 Fifth Street, Suite 500
New York, NY 10010
Re:MiNK Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 13, 2024
File No. 333-281522
Dear Jennifer S. Buell, Ph.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Zachary R. Blume